Clinical trial · Interventional
Pantoprazole in Cisplatin Nephrotoxicity
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
NCT04217512CI-TRIAL-00042585recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pantoprazole in Cisplatin Nephrotoxicity
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Pantoprazole high dose | Drug | — | UNRESOLVED |
| Pantoprazole low dose | Drug | — | UNRESOLVED |
| Standard hydration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Standard hydration alone
- description
- Cisplatin with standard hydration
- interventionNames
- Other: Standard hydration
- Drug: Cisplatin
- type
- ACTIVE_COMPARATOR
- label
- Pantoprazole high dose
- description
- Cisplatin with standard hydration with pantoprazole 1.6 mg/kg
- interventionNames
- Drug: Pantoprazole high dose
- Other: Standard hydration
- Drug: Cisplatin
- type
- ACTIVE_COMPARATOR
- label
- Pantoprazole Low dose
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with head and neck cancer Exclusion Criteria: * GFR less than 59. * DM * Elevated liver enzymes more than 3 fold.
References
Publications (0)
Data not yet available
No reference posted for this study.